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Abstract
The first step in branched-chain amino acid (BCAA) catabolism is catalyzed by the
two BCAA transferase isoenzymes, cytoplasmic branched-chain amino acid trans-
ferase (BCAT) 1, and mitochondrial BCAT2. Defects in the second step of BCAA
catabolism cause maple syrup urine disease (MSUD), a condition which has been
far more extensively investigated. Here, we studied the consequences of BCAT2
deficiency, an ultra-rare condition in humans. We present genetic, clinical, and
functional data in five individuals from four different families with homozygous or
compound heterozygous BCAT2 mutations which were all detected following
abnormal biochemical profile results or familial mutation segregation studies. We
demonstrate that BCAT2 deficiency has a recognizable biochemical profile with
raised plasma BCAAs and, in contrast with MSUD, low-normal branched-chain
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keto acids (BCKAs) with undetectable L-allo-isoleucine. Interestingly, unlike in
MSUD, none of the individuals with BCAT2 deficiency developed acute encepha-
lopathy even with exceptionally high BCAA levels. We observed wide-ranging
clinical phenotypes in individuals with BCAT2 deficiency. While one adult was
apparently asymptomatic, three individuals had presented with developmental
delay and autistic features. We show that the biochemical characteristics of BCAT2
deficiency may be amenable to protein-restricted diet and that early treatment may
improve outcome in affected individuals. BCAT2 deficiency is an inborn error of
BCAA catabolism. At present, it is unclear whether developmental delay and
autism are parts of the variable phenotypic spectrum of this condition or coinciden-
tal. Further studies will be required to explore this.
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encephalopathy, maple syrup urine disease
1 | INTRODUCTION
There are three proteinogenic branched-chain amino acids
(BCAAs), leucine, isoleucine, and valine. The first enzymatic
step in BCAA metabolism is carried out by branched-chain
amino acid transferase (BCAT), a pyridoxine-dependent
enzyme which utilizes α-ketoglutarate to form branched-
chain α-keto acids (BCKAs) (Figure 1A).1 Expression of
BCATs is mainly extra-hepatic and is highest in the skeletal
muscle with some expression in adipose tissue, kidneys,
intestine, heart, and the brain.2 BCATs exist in two isoforms:
cytosolic (BCAT1) encoded by BCAT1 (OMIM 113520),
and mitochondrial (BCAT2) encoded by BCAT2 (OMIM
113530). These isoforms share 58% homology, but vary in
cellular location, tissue distribution, and catalytic efficiency.
Mitochondrial BCAT2 is the more ubiquitous of the two
isoforms.3 In humans, immunoreactivity for BCAT2 has been
shown to be present throughout the brain with consistent
labeling of vascular endothelial cells in the grey and white
matter, whereas the cytosolic BCAT1 is restricted to neu-
rons.3 Thus far, there has been only one genetically con-
firmed published case of BCAT2 deficiency in a 25-year-old
man with headaches and mild memory impairment without
developmental delay.4
In the liver, BCKAs undergo irreversible oxidative decar-
boxylation by BCKA-dehydrogenase complex (BCKDH)
and its cofactor thiamine (Figure 1A).5 Maple syrup urine
disease (MSUD, OMIM 248600) is a well-known disorder
of BCAA metabolism6; it is caused by defects in the
BCKADH complex mediated second step in the catabolism
of BCAAs7-9 (Figure 1A). The biochemical hallmarks of
MSUD are grossly elevated concentrations of BCAAs, espe-
cially leucine, and their corresponding BCKAs and
hydroxy-acids together with abnormal quantities for L-allo-
isoleucine.10 Untreated neonates with classical MSUD
develop life-threatening metabolic crisis with encephalopa-
thy but variant forms of MSUD with residual BCKDH activ-
ity may present later in life, for example, with
developmental delay, intermittent vomiting, or failure to
thrive. In affected individuals, metabolic stress due to inter-
current infections or prolonged fasting can precipitate severe
endogenous intoxication with acute encephalopathy and also
peripheral neuropathy.11 The chronic phenotype of MSUD
is largely attributed to the neurotoxicity of leucine resulting
in deficiency of several critical amino acids in the brain.12
The biochemical basis of acute toxicity along with encepha-
lopathy in MSUD is incompletely understood. It has been
shown in an animal model that chronic administration of
BCAAs at millimolar concentrations can cause significant
impairment in memory tasks in rats along with an increase
in brain-derived neurotrophic factor (BDNF) in the hippo-
campus and cerebral cortex, and that oxidative stress may
contribute BCAA-induced neurological impairment.13 How-
ever, the acute exposure of brains of young rats to the toxic
BCKA α-ketoisocaproic acid led to a decrease in BDNF as
well as nerve growth factor concentrations.14
Here, we describe the biochemical and clinical features
of five individuals with bi-allelic BCAT2 variants to estab-
lish the distinct metabolic profile of BCAT2 deficiency and
highlight the uncertainties of its clinical presentation.
2 | METHODS AND RESULTS
The study was approved by the local ethics committees
(UK NHS ethics committee 11/H1003/3; CEI-28-701 for
ethics committee of the Universidad Autónoma de Madrid,
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Spain, TSCUH research and ethics committee 12.043). All
procedures followed were in accordance with the ethical
standards of the responsible committee on human experi-
mentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000. Genetic testing was
performed according to Institutional Review Board (IRB)
approved guidelines or as part of clinical service with appro-
priate informed consent. We evaluated patients' characteris-
tics and compared available clinical, biochemical, and
molecular genetic findings.
Subject 1 is a 29-year-old Italian man with moderate
global developmental delay and autism spectrum disorder.
His full scale, verbal, and performance intelligence quotient
(Wechsler Adult Intelligence Scale, WAIS-R) scores at the
age of 28 years were 63, 67, and 59, respectively. We per-
formed trio (proband and both parents) whole exome
sequencing (WES) and identified a paternally inherited
BCAT2 c.545T>G (p.Val182Gly) and a maternally inherited
BCAT2 c.1021G>A (p.Ala341Thr) variant in the proband
(nomenclature according to the longest transcript NM_
001190, ENST00000316273.10) (Supplementary Methods).
No other likely causal pathogenic variants were identified.
Both BCAT2 variants were confirmed by Sanger sequencing
using standard methods (Figure 1B). Biochemical pheno-
typing15 revealed elevated valine, leucine, and isoleucine
concentrations in plasma (Table 1) (Supplementary
Methods).
Subject 2, an 11-year-old girl, was one of two children
born to consanguineous parents of Pakistani ancestry and
presented at the age of 2 years with global developmental
delay and microcephaly. She was diagnosed with learning
difficulties and ataxia along with signs of spastic para-
paresis. Her MRI brain at 8 years of age showed that the cor-
pus callosum was broad and globular in appearance and
also some mild cerebral T2 white matter hyperintensities
posteriorly (Figure 2). The proband has a younger brother
with global developmental delay and motor impairment. He
was detected to have a homozygous c.263dupG, p.
(Leu89fsTer13) variant in the exon 3 of B4GALNT1 via a
multigene next generation sequencing (NGS) panel. Bi-
allelic B4GALNT1 variants cause hereditary spastic paraple-
gia type 26 (OMIM # 609195,16). Testing in the proband
revealed that she too was homozygous for the frameshift
B4GALNT1 mutation. However, her initial biochemical
investigations also revealed elevated plasma valine, leucine,
and isoleucine concentrations (Table 1, Supplementary
Methods), organic acids including BCKAs were normal
(data not shown). She did not have any history of acute dete-
rioration or encephalopathy. We performed targeted BCAT2
Sanger sequencing and identified a novel homozygous non-
sense BCAT2 c.600C>A (p.Tyr200Ter) variant (Figure 1B).
FIGURE 1 Catabolism of branched-chain amino acids (BCAAs) and functional consequences of BCAT2 mutations. (A) Overview of shared
steps in catabolism of BCAAs and the biochemical profile of BCAT2 deficiency. In muscles, leucine, isoleucine, and valine undergo reversible
transamination to their respective branched-chain keto acids (BCKAs) by BCAA aminotransferase (BCAT). In liver, BCKAs undergo oxidative
decarboxylation catalyzed by BCKA-dehydrogenase complex (BCKDH). Subsequent degradation pathways of BCAA diverge. Maple syrup urine
disease is caused by BCKDH deficiency leading to grossly elevated BCAAs and their corresponding BCKAs and hydroxy-acids. In BCAT2
deficiency, BCAAs are excessively raised in plasma but the corresponding BCKAs were undetectable or low-normal (the biochemical profile is
provided in red font on the left side). (B) Chromatograms from Sanger sequencing. Parts of chromatograms of BCAT2 Sanger sequencing showing
compound heterozygous c.545T>G p.(Val182Gly) (marked by *) and c.1021G>A (p.Ala341Thr) (marked by **) mutations in subject 1;
homozygous nonsense c.600C>A (p.Tyr200Ter) in subject 2 (similar to subject 3); homozygous in-frame BCAT2 c.136_147 del; (p.
His46_Pro49del) in subject 4; and homozygous c.1154_1160delinsTGGATGCCCTCT (p.Ala385Valfs*35) in subject 5. All variants are named
according to NM_001190.3. (C) Location of homozygous or compound heterozygous BCAT2 variants. Wide and narrow blue boxes represent exons
and introns respectively. Brown and red ovals within exons depict missense and loss of function variants in the general population respectively. The
size of the ovals is proportional to the frequency of the variant. Red arrows depict the positions of the pathogenic mutations detected in individuals
with BCAT2 deficiency and font. Novel mutations reported in this study are underlined. Positions of homozygous variants in the general population
(from ExAC database) are depicted using blue arrows. (D) Protein structural analysis of BCAT2 variants. Left panel: the three novel missense and
deletion mutations in this study (shown as yellow sticks and spheres) are mapped onto the crystal structure of human BCAT2 (PDB code 1EKF),
which arranges as a homodimer (colored blue and pink chains), with each subunit containing an active site-bound PLP cofactor (shown as sticks).
Right panels: magnified views showing the local environment of the three sites of missense mutation (namely His46-Lys47-Lys48-Pro49, Val182,
and Ala341), as well as cartoon representation highlighting the regions of the BCAT2 protein deleted (red) for the two nonsense mutations.
(E) BCAT2 western blot analysis. Western blot analysis of protein extracted from cellular and nuclear lysates of fibroblasts from a control subject,
an individual with maple syrup urine disease (MSUD) and subject 5. BCAT2 protein was found to be completely absent in subject 5 with
homozygous c.1154_1160delinsTGGATGCCCTCT (p.Ala385Valfs*35) mutation. (F) BCAT activity analysis. Decarboxylation was measured in
the form of release of 14CO2 from L-[1-
14C]leucine and 14CO2 from L-[1-
14C] valine. Results are expressed as pmol/mg protein/hour. Data are
representative of three independent experiments and is given as mean ± SD (controls are shown with a hatching pattern). Significantly reduced
decarboxylation of leucine and valine was detected in fibroblasts from subject 4 (*, P < .05, Mann-Whitney U test). Leucine decarboxylation was
also measured in fibroblasts of subject 5 and that was reduced but not statistically significant (n.s.). These results support impaired BCAT activity
but do also point towards some residual decarboxylation capacity, possibly at cytosolic BCAT level
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Her clinical features did not respond to pyridoxine supple-
ments. Her brother and father were found to be carriers for
the familial BCAT2 variant.
Subject 3 is the mother of case 2; she underwent bio-
chemical and genetic testing after her daughter was identi-
fied with BCAT2 deficiency. The family also has two
unaffected children (2 years and 13 years old). The woman
did not report any acute symptoms and her systemic exami-
nation was entirely normal. She did not report any previous
major illnesses or complications during her four pregnancies.
Proband 3 does not have intellectual disability but we did
not perform any formal tests of cognition. Her baseline bio-
chemical investigations, while she continues to be on a nor-
mal diet, showed high BCAAs with no ketones/BCKAs or
allo-isoleucine detectable (Table 1).
Subject 4 is a 17-year-old boy of Irish ancestry with
severe speech and language impairment, intellectual disabil-
ity, and autism spectrum disorder. He had two words at
1 year of age and walked at 18 months. There was no further
progression in language skills and mannerisms occurred
around 2 years of age, such as hand flapping. A diagnosis of
autism was made at 2 years of age. He was first referred to
the metabolic department for an assessment when he was
4 years old. At the time, plasma amino acid measurements
showed exceptionally high levels of BCAAs (Table 1) with
undetectable L-allo-isoleucine, BCKAs, and ketones in
plasma and urine. He never had an altered state of con-
sciousness but he was admitted for further work-up in view
of his high BCAA concentrations; he underwent an urgent
CT brain scan which was normal. His high BCAA concen-
trations were confirmed in a separate blood sample (ie, leu-
cine 2067 μM/L, valine 4045, isoleucine 1677, L-allo-
isoleucine not detectable; for reference ranges see Table 1)
before he was commenced on a protein-restricted diet with
BCAA-free amino acids supplements. In terms of his adap-
tive functioning, he obtained an Adaptive Behavior Com-
posite (ABC) score of 43 (<1 percentile) on the Vineland
Adaptive Behavior Scales (2nd Edition, VABS-II, 2005) at
6 years of age.
His brain MRI showed mild nonspecific increased T2
FLAIR signal within the posterior periventricular white mat-
ter with a normal parenchymal signal elsewhere (Figure 2).
He also had a normal MR spectroscopy (MRS) at age
17 years (data not shown). We performed clinical targeted
BCAT2 Sanger sequencing and identified a novel homozy-
gous in-frame BCAT2 c.136_147del (p.His46_Pro49del)
FIGURE 2 MRI brain images of
subject 4 (17-year-old boy with
BCAT2 deficiency) and subject
2 (11-year-old girl with BCAT2
deficiency and hereditary spastic
paraplegia type 26). Axial T2 (A) and
T2 FLAIR sequence (B) demonstra-
ting mild increased T2 hyperintensity
within the posterior periventricular
white matter (white arrows) in subject
4 at 17 years of age. Mild nonspecific
increased T2 signal (C) in the posterior
cerebral white matter for her age in
subject 2 (axial T2 sequence at 8 years
of age) and slightly broad and globular
appearance of the corpus callosum
(sagittal T2) (D). BCAT2, branched-
chain amino acid transferase 2
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deletion (Figure 1B). This variant was confirmed to be het-
erozygous in the proband's father; the mother was not avail-
able for testing. While he responded biochemically well to
the diet (Table 1), there was no improvement in his clinical
features over the years (severe autism), and his diet was
relaxed during adolescence, again with no noticeable clinical
effect.
Subject 5, a Spanish girl of was identified to have slight
increase of valine on expanded newborn bloodspot screening
at 48 hours of age (312 μmol/L; normal range for newborns
54-270). On day 13 of life, further metabolic work-up was
performed including plasma BCAAs (Table 1). BCKAs, in
particular the leucine-derived metabolites, were normal or
only marginally detectable (data not shown). The girl was
commenced on a BCAA-restricted diet from 2 weeks of life
(Table 1). Targeted exome sequencing revealed a homozy-
gous frameshift c.1154_1160delinsTGGATGCCCTCT (p.
Ala385Valfs*35) BCAT2 deletion which was confirmed by
Sanger sequencing (Figure 1B). The girl continues to be on
a moderate BCAA-restricted diet with no additional supple-
ments with BCAA plasma concentrations close to normal
(Table 1). Currently, at 2.5 years of age she is developing
normally and is clinically asymptomatic.
We undertook in silico analysis of all the potentially
pathogenic variants identified in this study. We here
included two previously published compound heterozygous
BCAT2 variants (p.Arg170Gln and p.Glu264Lys) in our
analysis.4 We also included all the BCAT2 variants (p.His46-
Arg, p.Gln100Glu, p.Thr186Arg, and p.Thr319Ser) that
have been reported to be present in homozygous state in the
general population on the ExAC database (http://exac.
broadinstitute.org/gene/ENSG00000105552) (Figure 1C).
We used a pyridoxal phosphate (PLP) bound wild type
human BCAT2 structure (PDB accession code: 1ekf) to
examine the residue positions and visualize the site of the all
nine BCAT2 variants. Structural analysis was performed with
ICM Pro (Molsoft, LLC) (Figure 1D). The seven variants
identified in individuals with BCAT2 deficiency were
predicted to be damaging, whereas all the homozygous
ExAC variants were likely to be benign (Table S1)
(Figure 1D).
The mutation detected in subject 5 was present in the last
exon; however, western blot analysis (polyclonal anti-
BCAT2 #9432 antibody against peptide residues near the
amino terminus, Cell Signaling Technology) demonstrated a
total absence of BCAT2 in her fibroblasts (Figure 1E).
Oxidative decarboxylation rates for leucine and valine
were determined in cultured skin fibroblasts by measuring
release of 14CO2 from L-[1-
14C]leucine and L-[1-14C]valine,
respectively, by a modification of previous methodologies
(Supplementary methods). Release of 14CO2 from L-[1-
14C]
leucine and from L-[1-14C]valine was reduced in subject 4's
fibroblasts demonstrating reduced capacity of the cells to
metabolize leucine and valine (Figure 1F). Marked reduction
of [1-14C]leucine decarboxylation (18.3% of intra-assay con-
trol value) was also detected in fibroblasts from subject
5, confirming the pathogenicity of the homozygous frame-
shift variant (Figure 1F).
All individuals with pathogenic BCAT2 variants demon-
strated a distinct biochemical profile with raised plasma
BCAA levels (Table 1). Plasma valine concentrations in all
five individuals were considerably higher compared with
leucine or isoleucine. These findings are in line with our
studies performed on fibroblasts of subject 4 that showed a
more pronounced decrease in release of 14CO2 from [1-
14C]
valine (Figure 1F). Unlike in MSUD,10 BCKAs were low or
undetectable in individuals with BCAT deficiency even in
the presence of high BCAA concentrations. This is consis-
tent with the block at the BCAAs transamination level
(Figure 1A). We also did not observe an increase in L-allo-
isoleucine in these individuals with BCAT2 deficiency,
another biochemical marker differentiating this disorder
from MSUD17; this is because in vivo L-allo-isoleucine is
formed via retransamination of 3-methyl-2-oxopentanoate,
which is not formed in BCAT2 deficiency.
3 | DISCUSSION
NGS, or high-throughput sequencing, has transformed the
diagnosis of known and new rare diseases. We recently
showed the complementary value of NGS in diagnosis of
inborn errors of metabolism.18 In this study, a combination
of NGS and targeted Sanger sequencing guided or followed
by biochemical analysis leads to identification of five indi-
viduals with BCAT2 mutations. Homozygous null variants
were identified in subjects 2, 3, and 5. Subject 1 had com-
pound heterozygous missense variants, whereas subject
4 had a homozygous in-frame deletion. In silico analysis of
these variants supported their pathogenicity (Figure 1D)
(Table S1). Furthermore, none of these variants have been
described in the general population in homozygous state in
ExAC and gnomAD databases (https://www.biorxiv.org/
content/10.1101/531210v2.article-info19). Absence of pro-
tein was demonstrated in fibroblasts from subject 5 (Fig-
ure 1E). We demonstrated reduced enzyme activity in two
affected individuals (Figure 1F).
The biochemical phenotype of BCAT2 deficiency is dis-
tinct from MSUD and is characterized by raised plasma
BCAA levels in the absence of BCKAs and L-allo-isoleu-
cine. Remarkably, none of the individuals affected with
BCAT2 deficiency have ever developed acute encephalopa-
thy, although their plasma BCAAs were persistently ele-
vated, in some cases close to the acute encephalopathy range
of MSUD. Decreasing the plasma leucine is considered to be
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one of the primary goals of treatment of acute decompensa-
tion in MSUD.20 Our observations suggest that high levels
of BCAAs are unlikely to be solely responsible for acute
decompensation in MSUD and that partial blocking of
BCAT2 activity may be an additional therapeutic tool in the
future to treat acute episodes of MSUD.
Prior to our study, there has been only one genetically
confirmed published case of BCAT2 deficiency, a 25-year-
old man (individual 6 in Table 1) with headaches and mild
memory impairment but no developmental delay.4 The clini-
cal findings of five additional individuals presented here
raise important questions about the clinical phenotype of
BCAT2 deficiency. It remains unclear at present if BCAT2
deficiency could present as an adult onset disorder (as in
individual 6) and the findings reported in younger subjects
may not reflect its true phenotype, comparable to, for exam-
ple, 3-methylglutaconic aciduria type 1, a rare inborn error
of leucine catabolism.21 However, none of the subjects pres-
ented here, which includes two adults, have a history of
headaches and mild memory impairment, and it is possible
that these two clinical features affect only some individuals
with BCAT2 deficiency. Furthermore, three of five individ-
uals presented had developmental delay and/or autistic fea-
tures. Notably, no other cause of developmental problems
was detected in subject 1 who underwent WES.
In subject 2 who was born to consanguineous parents, two
separate autosomal recessive conditions could be identified
along with a distinctive neurological phenotype which is
largely attributed to hereditary spastic paraplegia. Of note, both
conditions have different cytogenetic locations (19q13.33 for
BCAT2 and 12q13.3 for spastic paraplegia 26). As part of
family studies we detected one affected individual (subject 3)
with no obvious phenotype. However, two members of the
same family were included in this case series whereby one of
them had a compounded disorder which may contribute to the
phenotypic variability of BCAT2 deficiency described.
In most cases the genetic diagnosis of BCAT2 deficiency
was prompted by the biochemical analysis. Amino acid pro-
filing is usually performed in individuals with developmen-
tal problems. Hence, our detection of BCAT2 deficiency in
patients with developmental problems may be due to ascer-
tainment bias. However, we could demonstrate abnormal
brain MRI findings in subject 4 for which no other underly-
ing cause except BCAT2 deficiency could be identified.
Notably, BCAAs are important nitrogen donors for gluta-
mate, the major excitatory neurotransmitter, and γ-amino
butyric acid (GABA), a widely distributed inhibitory neuro-
transmitter in the brain.22,23 The coordinated activities of
BCAT1, BCAT2, as well as BCKDH are crucial for
maintaining the balance of glutamate and GABA in the brain.22
Dysregulation of both the neurotransmitters has been impli-
cated in pathogenesis of intellectual disability and autism.24
A protein-restricted diet in subject 4 after diagnosis
showed a dramatic reduction in the levels of BCAAs with an
overall static clinical presentation. Subject 5 (who has a null
mutation) was started on protein-restricted diet soon after
birth and she has not shown any signs of developmental
delay. These observations suggest that the biochemical
markers of BCAT2 deficiency may respond to dietary man-
agement. Importantly, the clinical course of subject 5 sug-
gests that early treatment of BCAT2 deficiency may be
crucial. However, larger cohorts of individuals with BCAT2
deficiency need to be studied to investigate the impact of
dietary management on the clinical aspects of this condition.
Interestingly, some individuals with MSUD are thought
to be responsive to thiamine, the cofactor for BCKDH.25
Similarly, pyridoxine supplementation in BCAT2 deficiency
may be be a potential treatment in individuals with missense
mutations where the cofactor may help to stabilize the
enzyme e.4 Subject 2 in our study, with a premature termina-
tion of the BCAT2 protein, did not respond to pyridoxine
treatment. Subject 4 was also commenced on a trial of pyri-
doxine (100 mg/day) at 16 years of age with no clinical
improvement (in addition to his protein-restricted diet which
was started when he was 4 years old). Of note, the in-frame
BCAT2 deletion in this individual is distant from the PLP
binding site.
Collectively, our study demonstrates that BCAT2 defi-
ciency is an inborn error of BCAA catabolism that results in a
distinctive biochemical profile with raised plasma BCAA levels
in the absence of BCKAs and L-allo-isoleucine. BCAT2 defi-
ciency may be associated with developmental delay and autism
spectrum disorder in some cases; however, its phenotype
appears to be extremely variable and further studies are needed
to explore the clinical consequences of BCAT2 deficiency in
more detail. Timely diagnosis and treatment may potentially
improve the outcome in clinically affected patients. Taken
together, our observations provide further insight into catabo-
lism of BCAAs and their genetic defects in humans.
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